Señales en vivo de MRNA | Maximiza tus Ganancias con Getagraph.com

VENDER 2798 min ago

@ $123.03

Emitido: 3 may 2024 @ 14:10

Retorno: 1.60%

Señal anterior: may 2 - 15:25

Señal anterior: Comprar

Retorno: -2.79 %

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Stats
Volumen de hoy	4.47M
Volumen promedio	3.94M
Capitalización de mercado	47.91B
EPS	$0.550 ( 2024-05-02 )
Próxima fecha de ganancias	( $-3.52 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.01
ATR14	$4.36 (3.49%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Afeyan Noubar	Sell	3 982	Common Stock
2024-05-01	Afeyan Noubar	Sell	4 572	Common Stock
2024-05-01	Afeyan Noubar	Sell	4 246	Common Stock
2024-05-01	Afeyan Noubar	Sell	1 500	Common Stock
2024-05-01	Afeyan Noubar	Sell	700	Common Stock

INSIDER POWER
28.77
Last 100 transactions
Buy: 522 719 \| Sell: 285 992

Volumen Correlación

Largo: 0.92 (very strong)

Corto: -0.70 (moderate negative)

Signal:(54) Neutral

Moderna Inc Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas
RMRM	-0.925

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Moderna Inc Correlación - Moneda/Commodity

0.86
( strong )

0.26
( neutral )

0.00
( neutral )

0.59
( weak )

-0.88
( strong negative )

Moderna Inc Finanzas

Annual	2023
Ingresos:	$6.75B
Beneficio Bruto:	$2.06B (30.52 %)
EPS:	$-12.34

FY	2023
Ingresos:	$6.75B
Beneficio Bruto:	$2.06B (30.52 %)
EPS:	$-12.34

FY	2022
Ingresos:	$19.26B
Beneficio Bruto:	$13.85B (71.88 %)
EPS:	$21.22

FY	2021
Ingresos:	$18.47B
Beneficio Bruto:	$15.85B (85.83 %)
EPS:	$30.31

Financial Reports:

No articles found.

Moderna Inc

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.